TURKU, FI / ACCESS Newswire / October 20, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the ...
Turku, Finland-based immunotherapy developer Faron tested its lead asset in combination with azacitidine. First and second-phase data resulted in an 85% objective response rate and a 45% complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback